티카르실린-클라불란산

티카르실린-클라불란산 화학적 특성, 용도, 생산

• Antimicrobial activity

  Activity is that of ticarcillin , the role of the inhibitor being to restore the activity against β-lactamase-producing strains that would otherwise hydrolyze the drug.

• Pharmacokinetics

  C_max 3 g ticarcillin + 100 mg: 330 mg/L end: 8 mg/L end
  clavulanate intravenous: infusion: infusion
  infusion (30 min)
  Plasma half-life: 1.1 h 1.1 h
  Plasma protein binding: 45% 25%
  The pharmacokinetics of the two agents are mutually unaffected by co-administration. Ticarcillin can be detected in tissues and interstitial fluid following parenteral administration. Penetration into bile, peritoneal fluid and pleural fluid has been demonstrated. Concentrations in blister fluid were significantly lower than those in serum.
  Around 60–70% of ticarcillin and 35–45% of clavulanic acid are excreted unchanged in urine during the first 6 h after administration of a single dose of the mixture.

• Clinical Use

  Septicemia, including bacteremia
  Lower respiratory infections
  Bone and joint infections
  Skin and skin structure infections
  Urinary tract infections (complicated and uncomplicated)
  Gynecological infections, endometritis
  Intra-abdominal infections, peritonitis
  Its main use is in infections in which Ps. aeruginosa is suspected or proven.

• 부작용

  Adverse reactions associated with ticarcillin occur . As with co-amoxiclav, there is a risk of cholestatic jaundice . Pseudomembranous colitis has been reported.

티카르실린-클라불란산 공급 업체

Global(30)Suppliers

티카르실린-클라불란산 관련 검색